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Practice Points 
 Level of access to MS Specialists by people with progressive MS in the UK was high 
at 95%. 
 The most utilised practitioners by participants for their MS were MS specialist 
Doctor/Nurses, General Practitioners and Physiotherapists.  
 Level of access to a regular clinical review was 74%; however, 37% received their 
review less than annually, falling short of the recommended guidelines.  
 3 
Abstract 
Background: According to current UK guidelines everyone with progressive MS should 
have access to an MS Specialist but levels of access and use of clinical services is unknown. 
Our objective was to investigate access to MS Specialists, use of clinical services and 
disease-modifying therapies (DMTs) by people with progressive MS in the United Kingdom. 
Methods: A UK wide, online survey was conducted via the UK MS Register. Inclusion 
criteria: age over 18 years, primary or secondary progressive MS and a member of the UK 
MS Register. Participants were asked about access to MS Specialists; recent clinical service 
use; receipt of regular review and current and previous DMT use. Participant demographics; 
quality of life and disease impact measures were supplied from the UK MS Register. 
Results: In total 1298 participants responded: 5% were currently taking DMT; 23% had 
previously taken DMT; and 95% reported access to an MS Specialist. Most utilised services 
were: MS Doctor/Nurse (50%), General Practitioner (45%), and Physiotherapist (40%). 
Seventy-four percent received a regular review although 37% received theirs less than 
annually. Current DMT use was associated with better quality of life but past DMT use was 
associated with poorer quality of life and higher impact of disease.  
Conclusions: Access to, and use of, MS Specialists was high. However a gap in service 
provision was highlighted in both receiving and frequency of regular reviews.  
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INTRODUCTION 
Multiple Sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the 
central nervous system resulting in axonal and grey matter loss. It is estimated that there are 
130,000 people living with MS in the United Kingdom (UK).
1
 At time of diagnosis, 
approximately 15% of people with MS are diagnosed with Primary Progressive MS (PPMS), 
80% with Relapsing Remitting MS (RRMS) and 5% with Progressive Relapsing MS; and 
approximately 80% of those with RRMS will go on to develop Secondary Progressive MS 
(SPMS).
2
 
Disease-modifying therapies (DMTs) are currently available to those who have 
RRMS, or are still experiencing relapses in the early stages of SPMS. Disease-modifying 
therapies have been found to delay the transition from RRMS to SPMS.
3
 Until recently there 
were no effective licensed pharmacological treatments for slowing the progression of 
disability in either primary or secondary progressive MS, however Ocrelizumab has now 
been shown to decrease disability progression by 25% in people with primary progressive 
MS.
3
 Due to the lack of available effective pharmacological treatments for disease activity in 
progressive MS, specialist rehabilitation services are of particular importance. Despite this, 
access to specialist services throughout the UK can be difficult, and people with progressive 
MS are often told that there is little available for them, and advised to self-manage their 
condition.
4
 The International Progressive MS Alliance has subsequently highlighted 
rehabilitation for people with progressive MS as a research priority,
5
 and disciplines such as 
physiotherapy have positive evidence in the rehabilitation of people with progressive MS.
6
  
The current National Institute for Health and Care Excellence (NICE) guidelines for multiple 
sclerosis and Healthcare Improvement Scotland clinical standards for Neurological Health 
Services state that everyone with MS in the UK should have access to an MS Specialist and 
receive a comprehensive regular review at least annually, by a member of the multi-
 5 
disciplinary MS team.
7,8
 This review should cover all aspects of care (including medication, 
symptom management, disease course, general health, participation and social care needs) 
and does not have to be conducted in a clinical environment. Recently, MS Specialist Nurses 
were found to be the most consulted health care professional
9
 and 86% of people with MS 
reportedly had access to a Neurologist or MS Nurse.
10
 However, these studies did not 
differentiate between MS types. In some areas within the UK, such as London and Northern 
Ireland, a limited MS service provision has been found.
11,12
 Furthermore in England and 
Wales 55% of patient comments regarding provision of NHS MS services were negative.
13
  
The purpose of this study was to investigate access to, and use of, clinical services for people 
with primary and secondary progressive MS. Specifically exploring whether people with 
progressive MS had access to an MS Specialist; what clinical services they used; if they 
received an regular review; their current and previous use of DMT and to explore any 
associations between these variables and quality of life and physical and psychological 
impact of MS.  
 
METHODS 
The UK MS Register is an online register funded by the MS Society. People with MS 
become members voluntarily, and answer both regular and online surveys.
14
 Members self-
report their MS diagnosis type, demographical information and complete self-report outcome 
measures, such as the EQ-5D-3L Health Questionnaire (EQ-5D-3L) and the physical and 
psychological sub-scales of the Multiple Sclerosis Impact Scale-29 version 2 (MSIS-29) 
every three months. Data are anonymised using the Secure Anonymised Information Linkage 
system.
15
 At the time of this study there were 11,041 people on the UK MS Register with 
4,384 people active on the Register in the previous six months. 
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Design and Participant Recruitment 
A cross-sectional survey design was used. The survey was available on the UK MS 
Register from August to October 2015. To be eligible for inclusion a participant had to be 18 
years old or over, living in the UK, diagnosed with progressive MS and registered on the UK 
MS Register. Potential participants were identified by the UK MS Register, and emailed 
informing them of the survey. The survey was accessed only via the UK MS Register, and 
completion was regarded as informed consent. Ethics approval was obtained from the 
College of Medical, Veterinary & Life Sciences Ethics Committee, University of Glasgow 
and the study underwent peer review by the information governance panel of the UK MS 
Register (South West - Central Bristol Research Ethics Committee, Ref: 11/SW/0160). 
The survey was in two sections. The first asked about access to, experiences and opinion of 
physiotherapy services and complementary therapies in the UK, and has been described 
elsewhere.
16
 The second section asked if a participant had access to an MS Specialist: defined 
as a clinician with MS Specialist skills. Participants were also asked which clinicians they 
consulted in the previous three months for their MS. Participants were asked if they received 
a regular review for their MS; how often that review took place; who normally undertook the 
review; and where the review normally took place. Finally, previous and current use of DMT 
was explored and participants were asked to select whether they were currently taking, or had 
previously taken, any of the following: Beta-interferon (Rebif, Avonex, Betaferon), 
Glatiramer acetate (Copaxone), Dimethyl fumarate (Tecfidera), Teriflunomide (Aubagio), 
Natalizumab (Tysabri, Antigren), Fingolimod (Gilenya, Novartis), Mitoxantrone 
(novantrone), and Alemtuzumab (Lemtrada). A copy of the survey is available on request. 
Due to the structural progression of the survey not all participants answered all questions.  
 
Access 
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This study explored two components of access: the opportunity to enter into the 
service (regardless of organisational barriers such as waiting times and distance to travel) and 
the utilisation of services.
17
 In this survey these two terms were referred to as ‘access’ and 
‘use’ respectively. Whilst these terms were not explicitly explained the meaning was implied 
by questions asked, for example “Which of the following clinicians could you see if you 
wanted to?” implied the availability of the opportunity to see a clinician and “Which of the 
following clinicians have you seen in the past three months for your MS?” implied the 
utilisation of services. Barriers to accessing physiotherapy were explored in some detail and 
have been published elsewhere.
16
 
 
Access to an MS Specialist 
Participants were asked if they had access to an MS Specialist service. If they 
answered ‘yes’ they were then asked which clinicians they had seen recently for their MS. If 
they answered ‘no’ they were then asked which clinicians they could see if they wanted to. 
Included in this list were ‘MS Specialist Nurse’ and ‘MS Specialist Doctor/ Neurologist’. The 
answers of those who reported having access to an MS Specialist service and of those who 
reported they could see an MS Specialist Nurse or Doctor were combined. This gave the total 
level of access to MS Specialists of this cohort.  
 
Additional Data from UK MS Register  
In addition to data collected from the survey, the following data routinely collected by 
the UK MS Register were accessed: type of MS; age; gender; time since diagnosis of MS; 
quality of life measured by the EQ-5D-3L; the physical and psychological sub-scales of the 
MSIS-29; Lower Super Output Area codes [England and Wales] and Output Area codes 
[Scotland] (there were no available geographical data for participants from Northern Ireland). 
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Lower Super Output Area codes and Output Area codes, which are used to tabulate census 
and statistical data by the Office of National Statistics, were combined with data available 
from the Office for National Statistics and the Scottish Office for National Statistics
18,19
 to 
generate the following: rural or urban dwelling, and Strategic Health Authority for 
participants in England (in 2013 NHS England divided England into ten regions called 
Strategic Health Authorities each of which contained multiple NHS trusts). Rural dwelling 
was defined as a settlement with a population of 10,000 or less.
20
  
The EQ-5D-3L is a self-report measure of quality of life generating an index ranging 
from -1 to 1, a higher index indicating a better quality of life.
21
 The MSIS-29 is a 29-item 
self-report measure with physical and psychological sub-scales to measure the impact of 
MS.
22
 The physical sub-scale ranges from 20-80 and the psychological sub-scale ranges from 
9-36. A lower score indicates a lower impact of MS.  
 
Data Analysis 
Data were analysed using IBM SPSS v22. Descriptive statistics were used to 
characterise demographic data and all outcome variables. The responses to individual 
questions are presented as percentages. Data were tested for normality and due to non-normal 
distribution Chi-square and Mann-Whitney tests were used as appropriate. A significance 
level of p < .05 was used.  
 
RESULTS 
In total 2,538 registrants with progressive MS were emailed by the UK MS register, 
and 1,298 participants completed the survey generating a 51% response rate; England 
(n=1,030), Scotland (n=130), Wales (n=104) and Northern Ireland (n=21). Participants had a 
mean age of 59 (SD 8) years and time since diagnosis of 16 (SD 9) years; the female to male 
 9 
ratio was 1.7: 1; 37% had PPMS (n=486) and 63% had SPMS (n=812). Mean EQ-5D-3L 
index was 0.49 ± SD 0.2, indicating a poorer quality of life compared to general population 
of the same age who would have an approximate index of 0.8.
23
 The mean MSIS-29 physical 
and psychological sub-scores were 55.97 (SD 12.64) and 19.96 (SD 6.10) respectively 
indicating that this sample was moderately affected both physically and psychologically by 
their MS (Table 1). Compared to those with SPMS, people with PPMS were younger, had a 
shorter time since diagnosis, had a higher EQ-5D-3L index and lower psychological and 
physical scores on the MSIS-29 (all p < .005).  
In total 95% (n=1,184) of participants reported that they had access to an MS 
Specialist, and 96% (n=959) of those who had access reported they would be able to access 
the specialist if their symptoms or needs changed. Figure 1 shows access to MS Specialists 
across the UK. Access to an MS Specialist ranged from 92% in Yorkshire and the Humber 
and the East Midlands to 98% in Wales.  
Overall, 81% (n=1046) of participants reported using clinical services for their MS in 
the previous three months. The most commonly used clinical services were MS Specialist 
Doctor/Nurse (50%, n=517), General Practitioner (45%, n=467), and Physiotherapist (40%, 
n=414) (Figure 2). Of the participants receiving clinical services for their MS: 46% (n=481) 
were receiving a single service and 54% (n=565) were receiving more than one service. From 
those who answered the question 20% (n=88) of participants reported they were currently 
taking DMT (PPMS n=18, SPMS n=70), and 24% (n=303) reported that they had previously 
taken DMT (PPMS n=37, SPMS n=266). These numbers equated to 5% and 23% of the total 
sample respectively.  
In total, 74% (n=917) of participants received a regular review; 56% (n=505) received 
that review annually; 63% (n=569) had their review performed by an MS Specialist Doctor 
and 27% (n=248) reported it was performed by a nurse. A total of 90% (n=819) reported 
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usually receiving their review in a hospital or clinic (Table 2). Ninety percent of participants 
who were currently taking a DMT received a regular review: 6% received their review twice 
a year, 51% once a year, 41% less frequently than once a year and 2% did not know (not 
shown in tables). 
There was a statistically significant association between access to an MS Specialist 
and receiving a regular review (p < .001) (Table 3). Access to an MS Specialist was not 
associated with MS type, past or present DMT use, or urban/rural dwelling (Table 3). 
Participants who were in receipt of a single clinical service, as opposed to multiple services, 
for their MS had a better quality of life as measured by the EQ-5D-3L index (p < .001), and 
less of a physical and psychological impact of MS as measured by the MSIS-29 (p < .001). 
Use of single or multiple services was, however, not dependent on MS type (n=1045, p = 
.165) or whether a participant lived in a rural or urban location (n=1003, p = .972) (not shown 
in tables). Participants who were currently taking DMT for their MS had a better quality of 
life (p = .016) than those who were not taking DMT. Those who had previously taken DMT, 
however, had a poorer quality of life (p < .001), and greater physical (p < .001) and 
psychological (p = .006) impact than those who had not taken DMTs (Table 4). There were 
no differences in quality of life and disease impact scores between those who did and did not 
have access to an MS Specialist or access to a review and there was no difference in the 
psychological or physical impact of MS between those who were and were not currently 
taking DMT (Table 4). 
 
DISCUSSION 
This study had the largest sample solely of people with progressive MS to be 
surveyed to date, and was the first to investigate access to, and use of clinical services for 
people with progressive forms of MS across the UK.  
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In this sample of 1298, access to an MS Specialist was high (95%) and was similar 
across the UK (Figure 1). This was slightly higher than the outcome of a survey carried by 
the MS Society in people with all types of MS in the UK which reported 86% of participants 
had access to a Neurologist or MS Nurse.
10
 A previous study conducted in London reported a 
lack of access to MS related services amongst those severely affected by MS
11
 however the 
present study indicates that 95% of people with progressive MS have access to an MS 
Specialist. This difference in results may indicate improvements in service provision, since 
Edmonds et al.
11
 carried out their study and that the people in this sample were not severely 
affected by their MS. Interestingly there were no differences in quality of life and disease 
impact measures between those who did and those who did not have access to an MS 
Specialist. However, there were only a relatively small number of people who did not have 
access in these analyses so results should be interpreted with caution. 
While access to MS Specialists was high not all received a regular review, as is 
recommended by current guidelines and standards.
7,8
 Just under three quarters of participants 
received a regular review and 37% of these received their review less frequently than 
annually. This is a breach of the National Institute for Healthcare and Excellence guidelines 
and the Healthcare Improvement for Scotland clinical standards. With the potential advent of 
pharmacological treatments for PPMS disease activity
3
 a regular clinical review will in the 
future be particularly important in the care of people with progressive MS. Indeed of those 
who were currently receiving a DMT, 90% were in receipt of a regular review but only 57% 
received that review once a year or more frequently. However, it should be noted that there 
were no differences in quality of life or disease impact measures between those who did and 
did not receive a regular review.  
Use of clinical services in this study’s participants was high. The three most utilised 
clinical services were MS Specialist Nurse or Doctor, General Practitioner, and 
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Physiotherapist (Figure 2). This finding was similar to two previous studies surveying people 
with all types of MS in the UK and in Europe.
9,24
 This may indicate that people with 
progressive MS are using the same kind of clinical services to those with RRMS.  
Similar proportions of participants received multiple services (54%) or a single service (46%) 
for their MS. Those who received a single service for their MS had a better quality of life and 
lower psychological and physical impact of MS compared to those who received multiple 
services, which may be a reflection of clinical need and in turn likely to be associated with 
disability level.  
There was no association between rural or urban dwelling and access to an MS 
Specialist or receiving a regular review. Previous research by Lonergan et al. in the Republic 
of Ireland found a lack of access to services was associated with rural dwelling.
25
 These 
researchers however surveyed people with all types of MS, and in addition 37% of the 
population live rurally in the Republic of Ireland, compared to 18% in the UK
26
 which may 
explain the differences in results reported. Furthermore, the lack of association between rural 
and urban living and access to an MS Specialist may be due to the definition of access used in 
this study being the opportunity to see a clinician regardless of personal and organisational 
barriers.  
Five percent of this sample was currently taking DMT and 23% had been prescribed 
them previously. This result is lower than previously reported by the MS Society which 
found 56% of all people with all types of MS in UK were taking DMT.
10
 This difference is 
expected as prescribing guidelines state that DMT are not effective in progressive forms of 
MS when relapses are not present
27
 and that those on DMT currently may have been 
prescribed them whilst in the relapsing-remitting phase of MS. The five percent of 
participants still taking DMT does however, contribute further to the importance of a regular 
clinical review as there are potentially a large number of people with MS inappropriately 
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taking these drugs in the UK. Furthermore those taking DMT had a better quality of life 
compared to those who were not. Those who had previously taken DMT however, had a 
poorer quality of life and a greater physical and psychological impact of MS compared to 
those who had never taken them. These differences were however small and may be an 
indication of the stage of disease, as those who are no longer taking DMT may have more 
advanced disease, and transitioned into the secondary progressive phase for which DMTs are 
no longer appropriate. 
 
Study Limitations 
The open and voluntary nature of the UK MS Register and online surveys leave the 
sample open to bias to the motivated and those with a vested interest. In addition those who 
are more severely disabled and find it difficult to access services may not be on the register. 
The diagnosis and type of MS was self-reported, however in future the UK MS Register will 
be linked with clinical data from the NHS. The concept of access is multi-faceted and even 
though the definition of access as the opportunity to see a clinician was implied by the 
questions asked, it was not implicitly defined which may have affected responses. For 
example if they felt that even their clinician was not available due to a long waiting list they 
may have selected that they did not have access. A programming error lead to the responses 
regarding access and use of MS Doctor and MS Nurse being combined and were thus 
combined in the results. There were no geographical data available for participants in 
Northern Ireland which limited the analysis comparing participants living in a rural and urban 
setting. Participants may have encountered problems with memory recall when asked 
regarding the regularity of review. This may have resulted in errors in reporting with those 
who more recently received their review being more likely to report it. Lastly due to the 
conditions of ethical approval it was not possible to examine the demographics of those who 
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did not respond to the survey to determine if they were typical of those registrants of the UK 
MS Register with progressive MS. 
 
CONCLUSION 
This was the first survey of its kind examining access and use of clinical services by 
people with progressive MS in the UK, and had the largest sample of people with progressive 
MS to date. Access to an MS Specialist was high and use of clinical services for participant’s 
MS was also high. However a gap in service provision, which is breaching national 
guidelines, was found in relation to regular reviews and health care providers in the UK 
should address this. Furthermore investigation should also establish the effectiveness and 
patient satisfaction of services used. 
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 Table 1. Demographics of survey participants 
  
Total 
(n=1298) 
PPMS  
(n=486) 
SPMS  
(n=812) 
Difference between 
PPMS and SPMS 
Age (years) 59 (8) 60 (8) 58 (9) p<.001
a
 
TSD (years) 16 (9) 12 (8) 19 (9) p<.001
a
 
Gender 
 
   
 Female  824 246 578 p<.001
b
 
 Male  474 240 234 - 
Country [where known]    
 Scotland  130 57 73 p=.343 
 England  1030 372 658 - 
 Wales  104 40 64 - 
 N. Ireland  21 9 12 - 
EQ-5D-3L index 0.49 (0.20) 0.52 (0.20) 0.48 (0.20) p=.001
a
 
MSIS-29 -psych 19.96 (6.10) 19.35 (6.05) 20.31 (6.11) p=.004
a
 
MSIS-29 - phys 55.97 (12.64) 54.46 (13.27) 56.88 (12.12) p=.002
a
 
 
Abbreviations: n: number of responses; TSD: Time Since Diagnosis; EQ-5D-3L: EQ-5D-3L 
Health Questionnaire; MSIS-29 psych: Multiple Sclerosis Impact Scale-29 psychological 
sub-scale; MSIS-29 phys: Multiple Sclerosis Impact Scale-29 physical sub-scale 
Figures where applicable are mean and SD. Not every participant had demographic data 
available, for example country of domicile. Mean time between survey completion and most 
recent EQ-5D-3L and MSIS-29 completions were 39 (120) and 19 (111) days. 
a
Statistically significant as calculated by Mann-Whitney tests.  
b
Statistically significant as calculated by Chi-square test.  
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Table 2. Survey responses regarding a regular review for progressive MS  
Question  Answer n % 
Are you offered a regular clinical review for 
your MS?  
Yes 917 74 
No  287 23 
(n=1243) Don’t know  39 3 
On average; how often is your  
review? 
Twice a year 57 6 
Once a year 505 55 
(n=912)
 
 Less frequently than once a year 341 37 
  Don’t know  9 1 
Who usually undertakes your  
review? 
MS Specialist Doctor/Neurologist 569 63 
GP 8 1 
(n=911) Nurse 248 27 
 
Physiotherapist 12 1 
 
Occupational therapist 6 1 
 
The person can vary 58 6 
 Other  10 1 
Where does your review normally take 
place?  
At home 43 5 
In a hospital or clinic 819 90 
(n=911) In a community centre 10 1 
 
GP surgery 20 2 
 Other  19 2 
 
Abbreviations: n: number of participants; GP: General Practitioner. 
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Table 3. Associations between access to an MS specialist and MS type, past and present 
DMT use, rural or urban living and receiving a regular review 
  n p 
Access to MS Specialist and PPMS or SPMS 1248 .473 
Access to MS Specialist and past DMT use 1227
a
 .371 
Access to MS Specialist and current DMT use 362
a
 .175 
Access to MS Specialist and urban/rural dwelling 1201 1.000 
Access to MS Specialist and regular review 1233 <.001
 b
 
 
Abbreviations: n: number of responses; PPMS: Primary Progressive Multiple Sclerosis; 
SPMS: Secondary Progressive Multiple Sclerosis; DMT: Disease Modifying Therapies. 
a
n is significantly higher than results of current and past DMT use reported in main text (88 
and 303 respectively) as Chi-square test also includes the participants who answered no.  
b
Statistically significant result from Chi-square test. 
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Table 4. Differences in EQ-5D-3L and MSIS-29 scores in those with and without access 
to an MS specialist, regular review, receiving more than one MS service, and current 
and past DMT use 
Access to MS specialist yes no 
 
 
n med n med p 
EQ-5D-3L index 1154 0.57 62 0.50 0.245 
MSIS-29 phys 1180 56.00 64 58.50 0.581 
MSIS-29 psych 1167 19.00 63 19.00 0.832 
Access to review  Yes no 
 
 
n med n med p 
EQ-5D-3L index 898 0.57 276 0.57 0.642 
MSIS-29 phys 914 56.00 286 58.00 0.187 
MSIS-29 psych 903 19.00 285 19.00 0.410 
Single/multiple services single multiple 
 
 
n med n med p 
EQ-5D-3L index 469 0.57 548 0.50 <0.001
a
 
MSIS-29 phys 478 55.00 563 59.00 <0.001
a
 
MSIS-29 psych 473 18.00 555 20.00 <0.001
a
 
 
yes no 
 Current DMT use n med n med p 
EQ-5D-3L index 87 0.57 346 0.50 0.016
 a
 
MSIS-29 phys 87 56.00 359 60.00 0.050 
MSIS-29 psych 85 20.00 357 20.00 0.960 
 
yes No 
 Past DMT Use n med n med p 
EQ-5D-3L index 296 0.50 912 0.57 <0.001
a
 
MSIS-29 phys 302 59.00 935 56.00 <0.001
a
 
MSIS-29 psych 299 20.00 925 19.00 0.006
 a
 
 
Abbreviations: n: number of responses; med: median; EQ-5D-3L: EQ-5D-3L Health 
Questionnaire; MSIS-29 psych: Multiple Sclerosis Impact Scale-29 psychological sub-scale; 
MSIS-29 phys: Multiple Sclerosis Impact Scale-29 physical sub-scale; DMT: Disease 
Modifying Therapies  
Not all participants had EQ-5D-3L or MSIS-29 data available. This accounts for slight 
variation in n. 
a
Statistically significant as calculated by Mann-Whitney tests.  
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Figure 1. Access to MS Specialists across the UK 
Access to MS Specialists by people with progressive MS within Scotland, Northern Ireland, 
Wales and the Strategic Health Authorities in England. 
 
 
Figure 2. Clinical services used for MS in the past three months 
Clinical services used by participants for their MS in the prior three months. Abbreviations: 
MSDr/NS: MS Doctor or MS Nurse; GP: General Practitioner; Physio: Physiotherapist; OT: 
Occupational Therapist; Cont NS: Continence Nurse; NS oth: Nurse other; Dr oth: Doctor 
other; Orth: Orthotist; SW: Social Worker; Oth: other; Psych: Psychologist; SLT: Speech and 
Language Therapist; Diet: Dietician 
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Figure 1 
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Figure 2 
 
 
 
 
 
